Oh No! No disclosure of Ohno drug company payment

Olympian Apolo Anton Ohno is a marketable commodity.

And drug company Teva Pharmaceuticals is riding those fast blades for all it can.

And media love reporting on how Ohno is now the “national face” of the exercise-induced brochospasm campaign sponsored by Teva, which gives the condition the acronym label of EIB.

Acronyms are hot in health care marketing these days: PE, ED, COPD, ACS, HSDD, PMDD, OAB – to name a few.  If you know all of these, well, we worry about you.

The Los Angeles Times jumped on EIB because of Ohno’s involvement, and published,5 Questions: Apolo Anton Ohno now making strides against asthma.”

Forget the questions for a minute.

Maybe one of the answers the Times should have provided was that Ohno is being paid by Teva for these appearances.

The Philadelphia Inquirer noted that:

One of the cultural trend-setters in the soul patch category, Olympic short-track speed skater Apolo Anton Ohno will try to help Teva Pharmaceuticals sell more of its asthma inhaler ProAir HFA.

Public education about exercise-induced bronchospasm and asthma can be a good thing.

We just think that news organizations should disclose it when people they interview are being paid by a drug company to do such interviews on behalf of its product line.

You might also like


Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.